Patients with chronic hepatitis C may be more sensitive to iron hepatotoxicity than patients with HEF-Hemochromatosis

Internal Medicine

Volumn 49, Issue 22, 2010, Pages 2371-2377

  Hayashi, Hisao ^a   Piperno, Alberto ^b   Tomosugi, Naohisa ^c   Hayashi, Kazuhiko ^d   Kimura, Fumiaki ^e   Wakusawa, Shinya ^f   Yano, Motoyoshi ^g   Tatsumi, Yasuaki ^a   Hattori, Ai ^a   Pelucchi, Sara ^b   Katano, Yoshiaki ^d   Goto, Hidemi ^d  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c KANAZAWA MEDICAL UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Tamano City Hospital   (Japan)

^f NAGOYA UNIVERSITY   (Japan)

^g Yokkaichi City Hospital   (Japan)

Author keywords

Body iron store; Hemochromatosis; Hepatitis C; Hepcidin; HFE; Venesection

Indexed keywords

ALANINE AMINOTRANSFERASE; FERRITIN; HEMOGLOBIN; HEPCIDIN; HFE PROTEIN; IRON; TRANSFERRIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD VOLUME; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HEMOGLOBIN DETERMINATION; HEPATITIS C; HORMONE BLOOD LEVEL; HUMAN; IRON BLOOD LEVEL; IRON DEPLETION; IRON STORAGE; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; PHLEBOTOMY; REPEAT PROCEDURE; TRANSFERRIN BLOOD LEVEL;

DISEASE SUSCEPTIBILITY; DRUG-INDUCED LIVER INJURY; FEMALE; HEMOCHROMATOSIS; HEPATITIS C, CHRONIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHLEBOTOMY;

EID: 78549279176     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.4088     Document Type: Article

References (23)

1. Feder JN, Gnirke A, Thomas W, et al. A novel MHC class 1-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 13: 399-408, 1996.
2. Alexander J, Kowdley KV. HFE-associated hereditary hemochromatosis. Genet Med 11: 307-313, 2009.
3. Hayashi H, Takikawa T, Nishimura N, et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic hepatitis C and excess hepatic iron. Am J Gastroenterol 89: 986-988, 1994.
4. Kato J, Kobune M, Nakamura T, et al. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 61: 8697-8702, 2001.
5. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 355: 2444-2451, 2006.
6. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 45: 806-816, 2007.
7. Nicolas G, Bennoun M, Devaux I, et al. Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98: 8780-8785, 2001.
8. Pigeon C, Ilyin G, Courselaud B, et al. A new mouse liverspecific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276: 7811-7819, 2001.
9. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internali zation. Science 306: 2090-2093, 2004.
10. Bridle KR, Frazer DM, Wilkins SJ, et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homeostasis. Lancet 361: 669-673, 2003.
11. van Dijk BAC, Laarakkers CM, Klaver SM, et al. Serum hepcidin levels are innately low in HFE-related haemochromatosis but differ between C282Y-homozygotes with elevated and normal ferritin levels. Br J Haematol 142: 979-985, 2008.
12. Piperno A, Girelli D, Nemeth E, et al. Blunted hepcidin response to oral iron challenge in HFE-related hemochromatosis. Blood 110: 4096-4100, 2007.
13. Fujita N, Sugimoto R, Motonichi S, et al. Patients with chronic hepatitis C achieving a sustained virological response to peginterferon and ribavirin therapy recover from impaired hepcidin secretion. J Hepatol 49: 702-710, 2008.
14. Girelli D, Pasino M, Goodnough JB, et al. Reduced serum hepcidin levels in patients with chronic hepatitis C. J Hepatol 51: 845-852, 2009.
15. Sohda T, Yanai J, Soejima H, Tamura K. Frequencies in the Japanese populations of the HFE gene. Biochem Genet 37: 63-68, 1999.
16. Murao N, Ishigai M, Yasuno H, et al. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom 21: 4033-4038, 2007.
17. Shiono Y, Hayashi H, Wakusawa S, et al. Iron stores and iron restoration rate in Japanese patients with chronic hepatitis C as measured during therapeutic iron removal revealed neither increased iron stores nor effects of C282Y and H63D mutations on iron indices. Nagoya J Med Sci 64: 51-57, 2001.
18. Kaneko Y, Miyajima H, Peperno A, et al. Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders. J Gastroenterol 2010 Jun 9 [Epub ahead of print].
19. Nishina S, Hino K, Korenaga M, et al. Hepatitis C virus-induced reactive oxygen species raise hepatic iron level in mice by reducing hepcidin transcription. Gastroenterology 134: 226-238, 2008.
20. Miura K, Taura K, Kodama Y, et al. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 48: 1420-1429, 2008.
21. Hayashi H, Takikawa T, Nishimura N, et al. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22: 268-271, 2005.
22. Piperno A, Fargion S, D'Alba R, et al. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol 16: 364-368, 1992.
23. Kimura F, Hayashi H, Yano M, et al. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C. Hepatogastroenterology 52: 563-566, 2005.